ADvantage Therapeutics

Executive Summary

ADvantage Therapeutics is a clinical-stage biotechnology company developing AD04™, a repurposed immunostimulant with disease-modifying potential in Alzheimer's disease. Based on positive Phase 2 data, the company is advancing toward pivotal trials. With a lean operational structure and a focus on neurodegenerative diseases, ADvantage represents a high-risk, high-reward opportunity in the Alzheimer's therapeutic landscape.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase 2b/3 pivotal trial for AD0470% success
• Q2 2026Publication of full Phase 2 results in peer-reviewed journal85% success
• TBDStrategic partnership or licensing deal for AD0440% success